scholarly journals Clinical Presentation and Management of Severe Acute Renal Failure in McArdle Disease

2021 ◽  
Vol 19 (2) ◽  
pp. 90-93
Author(s):  
Majdi Hamadeh ◽  
Khalil Nasrallah ◽  
Zeinab Ajami ◽  
Rahil Zeaiter ◽  
Layan Abbas ◽  
...  
Author(s):  
Kenan Cadirci ◽  
Mesut Aydin ◽  
Senay Arikan Durmaz ◽  
Afak Durur Karakaya ◽  
Yusuf Tanrikulu ◽  
...  

2008 ◽  
Vol 3;11 (5;3) ◽  
pp. 681-686
Author(s):  
Thomas M. Larkin

Objective: This is the first case describing an episode of acute renal failure occurring during a spinal cord stimulation trial. Clinical Presentation: A 48-year-old male with a history of hypertension and 3 prior failed spine surgeries underwent a trial of spinal cord stimulation for uncontrolled bilateral lower extremity neuropathic pain. Two days after the placement of the percutaneous stimulator lead the patient returned complaining of 3 syncopal episodes. He was found to be hypotensive and in acute renal failure with a creatinine of 8.1 and a BUN of 83. Intervention: The stimulator lead was immediately removed. The patient was admitted to the intensive care unit and responded promptly to rehydration and placement of a urinary catheter. His renal and urological work-ups revealed no significant abnormalities. Conclusion: The development of the episode of acute renal failure may have been influenced by the secondary effects of spinal cord stimulation. Since acute renal failure has never been associated with the use of spinal cord stimulation, this singular example does not by itself demonstrate a relationship. However, if future episodes are seen, a link between the 2 events could be drawn. For now, it is not clear if the development of this patient’s acute renal failure could, in part, be attributed to the use of the spinal cord stimulator or if it was merely coincidental in nature. We do feel it is useful for the clinician to understand the pathophysiologic changes associated with spinal cord stimulation and to see how, at least in theory, there could be a connection. Key words: acute renal failure, spinal cord stimulation


2015 ◽  
Vol 12 (1) ◽  
pp. 56-61
Author(s):  
Alper Alp ◽  
Hakan Akdam ◽  
Ibrahim Meteoglu ◽  
Emel Ceylan ◽  
Arzu Cengiz ◽  
...  

Abstract Sarcoidosis is a multisystem, immune-mediated, granulomatous disease. Clinical presentation of this disease may vary; in majority of cases (~90%) thoracic involvement is the leading sign. Although renal involvement is thought to be uncommon in sarcoidosis this entity may not be so rare. Hypercalcemia seems to be the most likely cause of sarcoidosis-associated renal disease, it can even cause acute renal failure in 1-2% of sarciodosis patients. Immediate treatment is appropriate whenever organ function is threatened or when symptoms are severe. We present a case of sarcoidosis with hypercalcemia excluding other clinical conditions, which may potentially confuse the diagnosis.


2007 ◽  
Vol 100 (3) ◽  
pp. 313-316 ◽  
Author(s):  
Jayasree Pillarisetti ◽  
Awad Ahmed

2007 ◽  
Vol 167 (8) ◽  
pp. 939-940 ◽  
Author(s):  
Ali Delibaş ◽  
Kenan Bek ◽  
Fatih Süheyl Ezgü ◽  
Gülay Demircin ◽  
Ayşegül Oksal ◽  
...  

1988 ◽  
Vol 22 (10) ◽  
pp. 778-780 ◽  
Author(s):  
Hilary A. Skluth ◽  
John E. Clark ◽  
George L. Ehringer

A case of a patient who had an acutely toxic reaction to cocaine ingestion and later developed acute renal failure secondary to rhabdomyolysis is described. Evidence of rhabdomyolysis was noted by the combination of myalgia, urine discoloration, and elevated serum concentrations of muscle enzymes. Although the mechanism of the rhabdomyolysis is unknown, the clinical presentation resembled that of a norepinephrine-induced vasoconstrictive effect that alters the metabolic demands of the muscle in such a way that the muscle is damaged.


2016 ◽  
Vol 36 (4) ◽  
pp. 406-408 ◽  
Author(s):  
Stéphane Torner ◽  
Claire Tinel ◽  
Zaara Soltani ◽  
Gérard Rifle ◽  
Christiane Mousson

1986 ◽  
Vol 20 (6) ◽  
pp. 421-438 ◽  
Author(s):  
Henry J. Mann ◽  
David W. Fuhs ◽  
Carl A. Hemstrom

Acute renal failure (ARF) is common among critically ill patients and renal dysfunction is often associated with the multisystem organ failure syndrome. The mortality of ARF remains high but animal data indicate that prevention and early treatment may decrease the morbidity and mortality. This review defines ARF based on urine volume, laboratory parameters, and clinical presentation. The pathophysiology of prerenal, postrenal, and intrinsic ART are differentiated and diagnostic criteria provided. Preventive therapy, supportive care, and proposed treatments are outlined. Studies examining the prevention and treatment of ARF in animal models and trials in humans are evaluated. Mannitol 0.5–1 g/kg, furosemide 0.5–1 mg/kg initially, and dopamine 1–5 μg/kg/min are effective in preventing or decreasing the severity of ARF in animal models. In humans these drugs are effective at maintaining urine output in various clinical situations and converting oliguria to nonoliguria in some patients; however, increased survival has not been adequately proven as of yet. Dialysis and experimental therapy are briefly discussed.


2016 ◽  
Vol 25 (01) ◽  
Author(s):  
Hasan Ergenç ◽  
Bilgehan Acar ◽  
Saadet Sayan ◽  
Savaş Sipahi

Sign in / Sign up

Export Citation Format

Share Document